CN115315266A - 人参皂苷组合物 - Google Patents

人参皂苷组合物 Download PDF

Info

Publication number
CN115315266A
CN115315266A CN202180022249.0A CN202180022249A CN115315266A CN 115315266 A CN115315266 A CN 115315266A CN 202180022249 A CN202180022249 A CN 202180022249A CN 115315266 A CN115315266 A CN 115315266A
Authority
CN
China
Prior art keywords
weight
ginsenosides
extract
composition
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180022249.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·莱克赞奈特
P·E·R·方卡-贝尔东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of CN115315266A publication Critical patent/CN115315266A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202180022249.0A 2020-03-20 2021-03-17 人参皂苷组合物 Pending CN115315266A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2004121.6 2020-03-20
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
GB2005288.2 2020-04-09
PCT/EP2021/056788 WO2021185890A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
CN115315266A true CN115315266A (zh) 2022-11-08

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180022249.0A Pending CN115315266A (zh) 2020-03-20 2021-03-17 人参皂苷组合物
CN202180022225.5A Pending CN115315264A (zh) 2020-03-20 2021-03-17 人参皂苷组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180022225.5A Pending CN115315264A (zh) 2020-03-20 2021-03-17 人参皂苷组合物

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315266A (https=)
AU (2) AU2021238639A1 (https=)
BR (2) BR112022015826A2 (https=)
CA (2) CA3174699A1 (https=)
WO (2) WO2021185890A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117752706A (zh) * 2023-12-20 2024-03-26 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185890A1 (en) * 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
JP7223754B2 (ja) 2017-07-18 2023-02-16 セネッセンス ライフ サイエンセズ プライベート リミテッド 認知機能の低下の治療および予防、また神経機能の保持に関する組成物およびその方法。
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用
WO2021185890A1 (en) 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW SCHOLEY等: "Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study", PSYCHOPHARMACOLOGY, vol. 212, no. 3, pages 345 - 356, XP019839039 *
兰乐霞;: "西洋参饮片治疗慢性疲劳综合征的有效性", 中国当代医药, no. 16, pages 117 - 118 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117752706A (zh) * 2023-12-20 2024-03-26 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用

Also Published As

Publication number Publication date
CA3174698A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
CN115315264A (zh) 2022-11-08
JP7808042B2 (ja) 2026-01-28
BR112022016241A2 (pt) 2022-10-11
US20230124503A1 (en) 2023-04-20
AU2021238639A1 (en) 2022-09-15
BR112022015826A2 (pt) 2022-10-04
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
WO2021185890A1 (en) 2021-09-23
AU2021238643A1 (en) 2022-10-20
JP2023518064A (ja) 2023-04-27
WO2021185897A1 (en) 2021-09-23
JP7850670B2 (ja) 2026-04-23
JP2023519189A (ja) 2023-05-10
CA3174699A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CN115315266A (zh) 人参皂苷组合物
Limanaqi et al. Potential antidepressant effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea
US6083932A (en) Pharmaceutical compositions derived from ginseng and methods of treatment using same
JP5491114B2 (ja) 薬草抽出物の化学的および薬理学的標準化
Zhang et al. Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20 (S)-protopanaxadiol in mice models of despair
Li Treatment of asthma and food allergy with herbal interventions from traditional Chinese medicine
WO2022127934A1 (zh) 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用
JP2013529899A (ja) ジンセノサイド成分を増加させた新規な加工人参または加工人参抽出物の製造方法
Lee et al. Changes in the ginsenoside content during the fermentation process using microbial strains
US20100278855A1 (en) Neuroprotective ganoderma compositions and methods of use
Yang Chinese ginseng
CN102233009B (zh) 一种促进神经再生的中药组合物及其制备方法和应用
Wei et al. Mahuang Fuzi Xixin decoction ameliorates allergic rhinitis and repairs the airway epithelial barrier by modulating the lung microbiota dysbiosis
AU2009258384B2 (en) Extract of Coptidis rhizoma and use thereof in treating respiratory disease
US11707497B2 (en) Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states
CN103932000B (zh) 一种复合双歧因子的灵芝孢子粉咀嚼片及其制备工艺
CN108014123A (zh) 臭氧化中草药、中药制剂提取物
TW201636036A (zh) 用於預防改善或治療身心俱疲症候群之組合物
JP2012533535A (ja) ジンセノサイド濃縮画分を含む血圧降下用組成物
Umar et al. In vivo antihyperglycaemic activity of crude and partitioned fractions of selected medicinal plants
US9956241B2 (en) Application of American Ginseng to enhance neurocognitive function
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
Cha et al. Effect of white, taegeuk, and red ginseng root extracts on insulin-stimulated glucose uptake in muscle cells and proliferation of β-cells
WO2015029134A1 (ja) ジンセノサイド組成物
Kim et al. Isolation of ginsenoside Rh1 and compound K from fermented ginseng and efficacy assessment on systemic anaphylactic shock

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination